The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial
NTDL980
Diode Laser 980-nm in Hemangioma Treatment
1 other identifier
interventional
15
1 country
1
Brief Summary
In an academic, government clinic, uni-center, randomized within patients trial study of the effects of 980-nm diode laser treatment included 15 cases of facial hemangiomas in patients with a history of discomfort due to lesions that were not suitable for removal using traditional methods. The study was carried out at the University of Baghdad/Institute of Laser for Postgraduate Studies/Laser Medicine Research Clinics from 15 October 2018 to 15 April 2019. Primary end-point is improvement of conditions at 6 months. Secondary end-points are quality of life, disappear lesions and safety administration of diode laser. Each patient received 12 sessions at two-week intervals. Lesions were photographed before and after laser treatment and digital image histograms were generated as a graphical representation of the tonal distribution. Following treatment, the lesions were less elevated, smoother in texture, and the color changed from dark red to light pink. There is a need to improve the treatment of face hemangiomas. Results from this randomized within patient trial will serve as preliminary evidence of the future role of diode laser in hemangioma treatment and a basis for design and power estimations of future studies. Based on the skin texture, color and elevation of the hemangioma as well as patient satisfaction, this type of laser is a safe and effective modality for the treatment of facial hemangioma in Iraqi patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2019
CompletedFirst Submitted
Initial submission to the registry
August 16, 2019
CompletedFirst Posted
Study publicly available on registry
August 22, 2019
CompletedAugust 22, 2019
August 1, 2019
10 months
August 16, 2019
August 20, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Area of Hemangioma lesions
Measured area of lesions by tape measure by centimeters
4th week
Color of lesion
By inspection color of lesion change from dark red to bright red or disappear
4 weeks
Shape of lesion
Clinical exam by inspection, we look to ugly shape of lesion, may be change for better or disappear
4 weeks
Study Arms (1)
Iraqi patients with face hemangioma
OTHERDiode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
Interventions
Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
Eligibility Criteria
You may qualify if:
- Comfortable.
- Superficial lesion.
You may not qualify if:
- Advanced case.
- Deep lesion.
- Uncomfortable.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Laser for Postgraduate Studies
Baghdad, 10001, Iraq
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
August 16, 2019
First Posted
August 22, 2019
Study Start
October 14, 2018
Primary Completion
July 30, 2019
Study Completion
August 15, 2019
Last Updated
August 22, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- one year
- Access Criteria
- Open
Data availability